Improvements in public health and medicine have lengthened human survival, but science has yet to overcome ageing.
They say aging is just a part of life, but have you ever wondered if it really has to be? What if getting older isn’t just something we accept but something we could actually treat?
In this riveting episode of Peak Human Labs Podcast, Dr. Sanjeev Goel, sits down with Dr. Aubrey de Grey, a trailblazing biomedical gerontologist and Chief Science Officer of the SENS Research Foundation. They dive deep into the revolutionary idea of treating aging as a medical condition. They explore how damage accumulates in our bodies over time and discuss the groundbreaking medical advancements that could extend our healthy lifespans. Dr. de Grey sheds light on the crucial need for investing in underfunded research and shares insights into the future of longevity science. Tune in and envision a future where health and longevity are not just aspirations but achievable realities!
Continue reading “How far till Longevity Escape Velocity?” »
Pigs are considered useful biomedical models for humans so the implications of such studies sent waves through the field of resuscitation — and bioethics.
At the recent annual International AIDS Conference, a startling presentation about the newest wonder drug in HIV prevention brought a raucous standing ovation.
But some of us in the public health community are now starting to wonder what all the cheering was about. Although the scientific results were impeccable, the process for translating those results into action for young women in Africa has been left to our imaginations. And if history is any guide, this could be a nightmare.
When the results first came out, Gilead, the manufacturer of lenacapavir, stated it was too early to discuss licensing and offering vague plans about its production and availability in Africa. Just recently, a second study among men who have sex with men and predominantly conducted in the Northern Hemisphere showed similarly promising results. While Gilead now says they have sufficient data to move ahead with licensing and manufacturing worldwide, they have offered no timeline to do so. Urgency to report trial results has not been mirrored by the urgency to provide access. Unanswered questions remain about why another study was needed to move ahead with approvals for use in African women, and if and when lenacapavir will be made available at an affordable price in the African region.
Implementation of new pricing and business structures and improved licensing and manufacturing processes could reduce the per-patient cost of gene therapy tenfold.
Scientists have used gene-editing techniques to boost the repair of nerve cells damaged in multiple sclerosis, a study shows. The innovative method, which was tested in mice, supports the development of cells that can repair the protective myelin coating around nerves, restoring their ability to conduct messages to the brain.
The findings, now published in Nature Communications, offer a potential route for future treatments to stop disability progression, experts say.
Our bodies have the ability to repair myelin, but in multiple sclerosis (MS), and as we age, this becomes less effective. There are currently no treatments to boost this process.
David Baker, Demis Hassabis and John M. Jumper revealed how amino acids shape protein structure, a finding that could aid in drug discovery.
Now a team of engineers and scientists from Caltech and the Keck School of Medicine of USC has developed a headset-based device that can be used to noninvasively assess a patient’s stroke risk by monitoring changes in blood flow and volume while a participant holds their breath.
Researchers in the lab of Caltech’s Changhuei Yang, along with colleagues from the Keck School of Medicine of USC, have developed a laser-based device that can measure blood flow noninvasively and differentiate stroke risk based on current physiological conditions.
